August 2026 in Oncology: FDA Approvals and Phase 3 Data Reshape Treatment Across Tumor Types

August 2026 delivered a series of notable regulatory and clinical milestones across solid tumors and hematologic malignancies. The FDA approved new treatment options for pancreatic, gastroesophageal, melanoma, and multiple myeloma indications, while pivotal trials reported potentially practice-changing findings in lung cancer, melanoma, and biliary tract cancer. For oncology pharmacists, August’s developments reinforce the expanding complexity of biomarker-directed treatment, combination therapy, individualized medicine, and toxicity management.

FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer

One of the most significant oncology developments of the month came on August 26, when the FDA approved daraxonrasib (Rasonque; Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy. The approval makes daraxonrasib the first approved therapy designed to broadly inhibit members of the RAS GTPase family in this setting.¹

The decision was supported by the randomized phase 3 RASolute 302 trial (NCT06625320), which enrolled 500 patients with metastatic pancreatic adenocarcinoma whose disease progressed after 1 prior systemic treatment. Daraxonrasib was compared with physician's choice of standard-of-care chemotherapy, with overall survival (OS) and progression-free survival (PFS) evaluated as major efficacy outcomes.¹

For pharmacists, the approval represents an important expansion of precision treatment in a disease where RAS alterations are extremely common but historically difficult to target. Daraxonrasib is administered orally once per day, bringing medication management, adherence, adverse event (AE) monitoring, and drug interaction assessment into an increasingly important role for pharmacy teams.¹

FDA Approves Zanidatamab-Based First-Line Regimens for HER2-Positive Gastroesophageal Cancers

On August 25, the FDA expanded the role of zanidatamab-hrii (Ziihera; Jazz Pharmaceuticals) into the first-line treatment of HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.²

The agency approved zanidatamab with fluoropyrimidine- and platinum-containing chemotherapy plus tislelizumab-jsgr (Tevimbra; BeOne Medicines) for tumors that are HER2 IHC 3+ or IHC 2+/ISH+. Zanidatamab plus chemotherapy without tislelizumab was also approved for patients with HER2 IHC 3+ disease. Two companion diagnostic devices received FDA approval alongside the regimens, further highlighting the importance of accurate biomarker testing before treatment selection.²

For oncology pharmacists, the new indication introduces additional complexity into frontline HER2-positive gastroesophageal cancer care, including regimen selection, immune-related AE surveillance when tislelizumab is incorporated, and management of toxicities associated with HER2-targeted treatment and cytotoxic chemotherapy.

FDA Grants Accelerated Approval to First CELMoD-Based Multiple Myeloma Regimen

The FDA granted accelerated approval on August 13 to iberdomide (Zenbexus; Bristol Myers Squibb) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least 1 prior therapy that included both a proteasome inhibitor and an immunomodulatory agent. Iberdomide is the first approved cereblon E3 ligase modulator (CELMoD), marking the arrival of a new therapeutic class in clinical multiple myeloma management.³

The approval was supported by the phase 3 EXCALIBER-RRMM trial (NCT04975997), which evaluated the iberdomide-containing regimen against daratumumab and hyaluronidase-fihj, bortezomib, and dexamethasone. The study randomized 939 patients across its 2 stages.³

The accelerated approval also carries a requirement for confirmation of clinical benefit.³ For pharmacists working in myeloma, the introduction of a CELMoD creates new considerations involving treatment sequencing, supportive care, toxicity monitoring, and patient education as clinicians integrate iberdomide among a rapidly expanding number of cellular therapies, bispecific antibodies, and targeted combinations.

FDA Approves Engineered Oncolytic Viral Therapy for PD-1–Refractory Melanoma

On August 6, the FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; Replimune) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed following a PD-1 inhibitor-based regimen.⁴

The genetically modified oncolytic viral therapy represents a distinct approach for patients with treatment-resistant disease. The FDA reported that about 1 in 4 patients responded to the combination, with a median duration of response approaching 14 months. The authorization under the accelerated approval pathway is based on objective response rate and duration of response and requires additional evidence to verify clinical benefit.⁴

Pharmacy teams will have an important role as viral therapies move further into routine oncology care, particularly around product handling, coordination of administration, patient counseling, and management of concomitant immunotherapy.

Trastuzumab Deruxtecan Improves PFS in First-Line HER2-Mutant Advanced NSCLC

Positive topline results from the phase 3 DESTINY-Lung04 trial announced August 17 could move HER2-directed antibody-drug conjugate (ADC) therapy substantially earlier in the treatment of non–small cell lung cancer (NSCLC).⁵

Trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo) produced a statistically significant and clinically meaningful improvement in PFS compared with platinum-pemetrexed chemotherapy plus pembrolizumab in patients with unresectable locally advanced or metastatic nonsquamous NSCLC harboring a HER2 exon 19 or 20 mutation.⁵

The trial enrolled 454 patients. OS remains under evaluation, and complete findings are expected to be presented at a future medical meeting. The results are particularly important because trastuzumab deruxtecan is already established in previously treated HER2-mutant metastatic NSCLC. A successful move into the first-line setting could make molecular testing for HER2 mutations even more consequential at diagnosis and heighten the pharmacist's role in monitoring ADC-associated toxicities, including interstitial lung disease/pneumonitis.

Osimertinib Plus Savolitinib Improves Both PFS and OS After EGFR TKI Resistance

Another major lung cancer readout arrived August 17 from the phase 3 SAFFRON trial. The combination of osimertinib (Tagrisso; AstraZeneca) and savolitinib (Orpathys; AstraZeneca, Hutchmed) achieved statistically significant and clinically meaningful improvements in both PFS and OS compared with platinum-doublet chemotherapy. The trial enrolled patients with EGFR-mutated NSCLC whose tumors demonstrated high levels of MET overexpression or amplification following progression on osimertinib.⁶

The findings are significant because MET amplification and overexpression represent important mechanisms of acquired resistance to EGFR-directed therapy. Rather than abandoning EGFR inhibition following progression, the strategy retains osimertinib as the therapeutic backbone while adding MET inhibition to address the resistance mechanism.⁶

For oncology pharmacists, the findings emphasize the growing importance of molecular reassessment following treatment failure and the need to understand how sequential targeted therapy can be guided by mechanisms of resistance rather than simply by line of treatment.

Personalized mRNA Therapy Achieves Positive Phase 3 Results in Resected Melanoma

August also brought a landmark result for individualized cancer therapy. On August 19, Merck and Moderna announced that the phase 3 INTerpath-001 trial (NCT05933577) evaluating intismeran autogene (V940/mRNA-4157) plus pembrolizumab met its primary end point of recurrence-free survival and the key secondary end point of distant metastasis-free survival. The study evaluated patients with completely resected stage IIB to IV melanoma and compared the individualized neoantigen therapy plus pembrolizumab with pembrolizumab alone.⁷

Intismeran is manufactured specifically for each patient using mutations identified in that patient's tumor to generate an individualized mRNA therapy designed to activate an immune response against tumor-specific neoantigens. According to the companies, INTerpath-001 represents the first positive phase 3 trial for an individualized neoantigen therapy and an mRNA-based cancer treatment. Detailed results have not yet been released, but the companies plan to present the findings at a future medical meeting and discuss regulatory submissions with health authorities.⁷

If approved, personalized manufacturing and coordination requirements could create an entirely new operational role for oncology pharmacy teams.

Ivonescimab Combination Beats Durvalumab Regimen in First-Line Biliary Tract Cancer Trial

Positive phase 3 findings from HARMONi-GI1 (NCT06591520) reported late in the month may also challenge an established immunotherapy-based standard in advanced biliary tract cancer. Also referred to as AK112-309, the randomized, double-blind trial compared ivonescimab plus chemotherapy with durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At a prespecified interim analysis, the ivonescimab regimen achieved a statistically significant and clinically meaningful improvement in OS, meeting the trial’s primary end point.⁸

The study also met key secondary end points of PFS and objective response rate. Ivonescimab is a bispecific antibody designed to target PD-1 and VEGF simultaneously, combining immune checkpoint blockade with inhibition of a major angiogenic pathway.⁸

Full data remain pending presentation and peer-reviewed publication, making the magnitude of benefit and safety profile important areas to watch. Still, demonstrating an OS advantage against an active durvalumab-containing comparator makes HARMONi-GI1 one of August’s most consequential late-stage oncology readouts.⁸

Looking Ahead

August 2026 illustrated how quickly oncology treatment paradigms continue to evolve. New approvals expanded options for difficult-to-treat pancreatic cancer and PD-1–refractory melanoma, while zanidatamab and iberdomide introduced new strategies in gastroesophageal cancer and multiple myeloma.^1-4

Simultaneously, positive phase 3 findings suggest additional shifts may be approaching. Trastuzumab deruxtecan could move HER2-targeted therapy into first-line HER2-mutant NSCLC, dual EGFR/MET inhibition may provide a more targeted response to acquired resistance, and individualized mRNA therapy has crossed a pivotal phase 3 threshold in melanoma.^5-7

For oncology pharmacists, these advances translate into increasingly biomarker-driven treatment selection, more complex combination regimens, and new medication management responsibilities that extend from conventional oral and intravenous therapy to antibody-drug conjugates, viral therapies, and individualized cancer vaccines.

REFERENCES

1. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. FDA. News release. August 26, 2026. Accessed August 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer

2. FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. FDA. News release. August 25, 2026. Accessed August 31, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction

3. FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma. FDA. News release. August 13, 2026. Accessed August 31, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

4. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. FDA. News release. August 6, 2026. Accessed August 31, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma

5. Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as first-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 phase 3 trial. AstraZeneca. News release. August 17, 2026. Accessed August 31, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-improved-pfs-in-1l-her2m-lung-cancer.html

6. Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso. AstraZeneca. News release. August 17, 2026. Accessed August 31, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/tagrisso-orpathys-improved-pfs-os-egfrm-lung.html

7. Merck. Merck and Moderna announce phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met end points of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Merck. News release. August 19, 2026. Accessed August 31, 2026. https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/

8. Ivonescimab plus chemotherapy demonstrates significant overall survival benefit versus durvalumab plus chemotherapy in first-line biliary tract cancer: HARMONi-GI1 meets primary endpoint. Akeso. News release. August 26, 2026. Accessed August 31, 2026. https://www.akesobio.com/en/media/akeso-news/260826/